Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 10/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | PRKX | P51817 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL27730596 | 0.93 | NOS1 (0.51) | NOS1AXLTRPA1TRPM8PLK4 | |
| SCHEMBL11577370 | 0.82 | NOS1 (0.60) | NOS1AXLTRPA1TRPM8PLK4 | |
| SCHEMBL6983718 | 0.81 | NOS1 (0.53) | NOS1AXLTRPA1TRPM8PLK4 | |
| SCHEMBL14738579 | 0.78 | NOS1 (0.50) | NOS1AXLTRPA1TRPM8PLK4 | |
| SCHEMBL22430426 | 0.75 | NOS1 (0.47) | NOS1AXLTRPA1TRPM8PLK4 | |
| SCHEMBL29520821 | 0.74 | TRPA1 (0.51) | NOS1TRPA1TRPM8PLK4CHEK1 | |
| SCHEMBL3519434 | 0.74 | NOS1 (0.59) | NOS1TRPA1PLK4CHEK1AURKA | |
| SCHEMBL20078879 | 0.73 | NOS1 (0.45) | NOS1AXLTRPA1PLK4CHEK1 | |
| SCHEMBL3064844 | 0.73 | NOS1 (0.63) | NOS1TRPA1PLK4CHEK1AURKA | |
| SCHEMBL29578522 | 0.72 | KDM4E (0.43) | AXLKDM4EMEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118525018-A | Bialkyne compound and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-7598286-B2 | [(1H-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1H-indazol-3-yl)methanones | WYETH (US) | 2009-10-06 | — | — | US | disclosed |
| US-20060106084-A1 | [(1H-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1H-indazol-3-yl)methanones | WYETH (US) | 2006-05-18 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| WO-2006050006-A2 | ((1H-INDAZOL-3-YL)METHYL) PHENOLS AND (HYDROXYPHENYL)(1H-INDAZOL-3-YL) METHANONES AS LIGANDS OF THE ESTROGEN RECEPTOR | WYETH (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-4096333-A | NITROSATION OF A 2-METHYLACETANILIDE | TENNECO CHEMICALS, INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-3988347-A | NITROSATION OF A 2-METHYL-ACETANILIDE WITH SODIUM NITRITE | TENNECO CHEMICALS, INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | NOS1 2864/4885AXL 1949/4885TRPA1 4861/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | NOS1 2864/4885AXL 1949/4885TRPA1 4861/4885 |
| US-20060106084-A1 | [(1H-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1H-indazol-3-yl)methanones | PTGS1, NOS3, PTGIS | NOS1 14/4885AXL 2384/4885TRPA1 434/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | NOS1 2370/4885AXL 2058/4885TRPA1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.